Generic Zembrace SymTouch Availability
Last updated on Jan 8, 2025.
Zembrace SymTouch is a brand name of sumatriptan, approved by the FDA in the following formulation(s):
ZEMBRACE SYMTOUCH (sumatriptan succinate - solution;subcutaneous)
-
Manufacturer: TONIX MEDS
Approval date: January 28, 2016
Strength(s): EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) [RLD]
Has a generic version of Zembrace SymTouch been approved?
No. There is currently no therapeutically equivalent version of Zembrace SymTouch available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zembrace SymTouch. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical composition for treating migraine
Patent 10,537,554
Issued: January 21, 2020
Inventor(s): Prabhakara Prabhu & Patil Rajesh Ramesh & Gupta Piyush & Raghuvanshi Rajeev Singh & Namboodiripad Anil N.
Assignee(s): UPSHER-SMITH LABORATORIES, LLCThe present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
Patent expiration dates:
- January 29, 2036✓
- January 29, 2036
-
Patent 11,364,224
Patent expiration dates:
- January 29, 2036✓
- January 29, 2036
-
Patent 12,097,183
Patent expiration dates:
- January 29, 2036✓
- January 29, 2036
More about Zembrace SymTouch (sumatriptan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antimigraine agents
- Breastfeeding
- En español
Patient resources
Other brands
Imitrex, Sumavel DosePro, Onzetra Xsail, Tosymra, ... +2 more
Professional resources
Other brands
Imitrex, Sumavel DosePro, Onzetra Xsail, Tosymra, Zecuity
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.